SPC389
Lungnahnettlu-fjölsykru sermigerð 22F sem er samtengt við CRM197 burðarprótín
Status:
VeittApplication date:
10.6.2022Application published:
15.7.2022Grant published:
15.7.2025
Max expiry date:
13.12.2036Medicine name:
VaxneuvanceMedicine for children:
No
Timeline
Today
10.6.2022Application
15.7.2022Publication
15.7.2025Registration
13.12.2036Expires
Marketing license
IS authorization number:
EU/1/21/1591/001-006Date:
31.12.2021
Foreign authorization number:
EU/1/21/1591Date:
13.12.2021
Owner
Name:
Pfizer Inc.Address:
66 Hudson Boulevard East, New York, NY 10001-2192 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP3096785
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 18.07.2025